CRISPR Therapeutics AG
Updated

Crispr consolidates, higher lows but with upward resistance

111
I stopped out on Crispr at 173.50 and since then the stock has consolidated setting higher lows while unable to break through resistance at around 173-173.50. This has had a significant impact on ARK-G which fed off the strong up-moves Crispr has made over the last six months.

It is believed that Crispr is the Apple of the future. Many times over Apple's price moves in the last decade, there were months and even years with little to no upward movement. For many, the buy and hold strategy may be the best approach.
Note
Still working neatly within the wedge. Time to plan for re-entry.

snapshot

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.